Blue Jet Healthcare Raises ₹800 Crore via QIP


    By Dalal Street Investment Journal (DSIJ)

    Summary :

     

    Blue Jet Healthcare share price gained 5% after the company completed a ₹800 crore Qualified Institutions Placement by allotting 1,58,10,276 equity shares at ₹506 per share. The issue saw participation from Shamyak Investment Private Limited and several ICICI Prudential mutual fund schemes.

    Blue Jet Healthcare Jumps 5%; Raises ₹800 Crore

    Blue Jet Healthcare share price was trading at ₹605.25 as of 10.15 AM on July 10, 2026, up 5% for the day. The stock touched an intraday high of ₹623.35 and a low of ₹596.10. Trading volume stood at 219 lakh shares compared with the 30-day average volume of 94.14 lakh shares. The elevated volumes on the day coincided with the company completing its qualified institutions placement, which drew participation from a systemically important NBFC and multiple mutual fund schemes.

    QIP Allotment Approved on July 9, 2026

    Blue Jet Healthcare Ltd has successfully conducted a Qualified Institutions Placement (QIP) whereby 1,58,10,276 equity shares of par value ₹2 per share have been allotted at the issue price of ₹506 per share (share premium of ₹504). The issue date is July 6, 2026, while the closure date is July 9, 2026. The allotment is authorised by the company’s Investment and Finance Committee in the meeting conducted on July 9, 2026.

    Blue Jet Healthcare Ltd

    Trade

    607.533.00 (5.74 %)

    Updated - 10 July 2026
    623.35day high
    DAY HIGH
    596.00day low
    DAY LOW
    546528
    VOLUME (BSE)

    Issue Price Set at 4.83% Discount to Floor Price

    The issue price of ₹506 per share was fixed at a discount of ₹25.70, representing 4.83% below the floor price. Offering shares at a discount to the floor price is a standard and permissible practice under SEBI's QIP framework, intended to make the placement more attractive to eligible qualified institutional buyers.

    Share Capital Expands Post-Allotment

    Following the allotment, Blue Jet Healthcare's paid-up equity share capital has increased from ₹34.69 crore, comprising 17,34,65,425 equity shares with a face value of ₹2 each, to ₹37.86 crore, comprising 18,92,75,701 equity shares of ₹2 each.

    Institutional Participation: Key Allottees

    Allottees with an issue of over 5% have been mentioned by the company. This is illustrated in the table given below:

    The allottee, namely Shamyak Investment Private Limited, which is a Systemically Important Non-Banking Financial Company, was found to be the single largest allottee of 34.38% of the total issue.

    Among the ICICI Prudential fund schemes, the Value Fund received the largest individual allocation at 10.47%, followed by the Manufacturing Fund at 8.15%. On a PAN-clubbed basis, the combined ICICI Prudential schemes accounted for 33.75% of the issue.

    S.No.

    Name of Allottee

    Shares Allotted

    % of Total Issue

    PAN-Clubbed Shares

    % (PAN-Clubbed, 5% & Above)

    Category

    1

    Shamyak Investment Private Ltd

    54,34,785

    34.38%

    54,34,785

    34.38%

    SI NBFC

    2

    ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

    9,19,996

    5.82%

      

    Mutual Fund

    3

    ICICI Prudential Manufacturing Fund

    12,87,994

    8.15%

      

    Mutual Fund

    4

    ICICI Prudential MNC Fund

    3,31,198

    2.09%

    53,35,974

    33.75% 

    Mutual Fund

    5

    ICICI Prudential Quant Fund

    36,800

    0.23%

      

    Mutual Fund

    6

    ICICI Prudential Equity Savings Fund

    9,19,996

    5.82%

      

    Mutual Fund

    7

    ICICI Prudential Value Fund

    16,55,991

    10.47%

      

    Mutual Fund

    8

    ICICI Prudential Quality Fund

    1,83,999

    1.16%

      

    Mutual Fund

    About Blue Jet Healthcare

    Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India

    Conclusion

    Successful completion of the QIP by Blue Jet Healthcare has led to the mobilisation of an investment of ₹800 crore through issuance of 1,58,10,276 equity shares priced at ₹506 per share. The QIP saw the participation of institutions such as a systemically important NBFC and a number of mutual fund schemes. Further communication on the utilisation of funds will be forthcoming from the company.

    Source: Dalal Street Investment Journal (DSIJ), BSE

    About the Author

    SEBI Registered Research Analyst (INH000006396).


    Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise. 

    Published Date : 10 Jul 2026

    Disclaimer :

    Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text